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ABSTRACT
Purpose: The somatostatin (SS) receptor subtype 2
(sst2) is the principal mediator of the antiproliferative ef-
fects of SS and has the highest affinity for the commercially
available SS analogues. The purpose of this study was to
evaluate sst2 mRNA expression by quantitative reverse
transcription-PCR (RT-PCR) in colon cancers and in cor-
responding normal tissues.
Experimental Design: The expression of sst2 mRNA was
measured with a quantitative method based on real time
RT-PCR with TaqMan assay in 100 colon cancers and in the
corresponding normal tissues. In a limited number of pa-
tients, these results were compared with those obtained by in
situ hybridization (n  26) and by in vivo imaging with
111In-pentetreotide (n  17).
Results: Results obtained by quantitative RT-PCR on
sst2 expression in colorectal cancer were significantly re-
lated to those obtained by in situ hybridization and 111In-
pentetreotide scintigraphy. Sst2 was expressed in all of the
tumors investigated without any relationship with localiza-
tion, grading, and stage of disease. Although the paired,
unaffected mucosa tends to express a higher abundance of
sst2 than the corresponding cancer samples, this difference
did not reach a statistical significance. However, in patients
with elevated carcinoembryonic antigen levels (>5 ng/ml)
there was a significant loss of sst2 mRNA in the tumor when
compared with its paired normal tissue.
Conclusions: In this study we confirmed, by a quanti-
tative method, that colorectal cancer does not express higher
concentrations of sst2 mRNA than the corresponding unaf-
fected tissue. Conversely, a loss of sst2 was found in patients
with elevated preoperative concentrations of carcinoembry-
onic antigen, an unfavorable prognostic marker for colorec-
tal cancer.
INTRODUCTION
Colorectal cancer is one of the major causes of cancer-
related mortality in the Western world. In Italy, 20,000–30,000
new cases of colorectal carcinoma are reported every year, with
the highest prevalence in patients above 65 years of age (1).
Advances made in the understanding of the disease, both in
terms of clinical behavior and molecular pathogenesis, have
been translated into improvements in its traditional therapy (2).
Despite this, many patients continue to succumb to the disease.
Therefore, it is important to identify new prognostic factors that
may allow additional insight into the optimal treatment strategy
for all patients. Although cancer stage is considered the most
important independent factor for survival or recurrence after
potentially curative surgery, many other independent factors
have been identified (3). One of these may involve the charac-
terization of SS3 receptors status.
SS is a ubiquitous peptide involved in multiple cellular
activities. In particular, SS regulates cell secretion and prolifer-
ation through a family of G-protein coupled receptor subtypes
(ssts; Ref. 4). The antiproliferative effect of SS is determined in
part indirectly through inhibition of the release of mitogenic
hormones and growth factors, through inhibition of angiogene-
sis, and in part directly through ssts located on cell mem-
branes (4).
Among the different sst subtypes identified recently (sst1-
sst5), sst2 mediates the antiproliferative effect more efficiently
than the others (5) and shows the highest affinity for SS ana-
logue octreotide (6). SS receptors, particularly sst2, are com-
monly overexpressed in a wide variety of neoplasms, especially
those arising from the neuroectoderm. Therefore, radiolabeled
SS analogues are useful in the management of well-differenti-
ated neuroendocrine malignancies such as carcinoid tumors (7).
In addition, many recent studies showed that sst2 is often highly
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expressed not only by tumors of the neuroendocrine system but
also by others, such as colorectal carcinoma (8–10).
Some recent studies have been performed to characterize
the pattern of expression of the different sst mRNA subtypes in
colon tumors, providing controversial results (11–13). Using
conventional qualitative RT-PCR, Buscail et al. (11) found a
heterogeneous expression of sst1-sst5 mRNA in colorectal car-
cinoma with a loss of sst2 mRNA expression in advanced
stages. In another study, using both RT-PCR and in situ hybrid-
ization, Laws et al. (12) observed a retained expression of sst2
mRNA but a decreased expression of sst5 mRNA in late stage
tumors. Vuaroqueaux et al. (13), using RT-PCR, showed that
sst5, sst1, and sst2 mRNA subtypes were the most frequently
expressed in a relatively large set of tumor and normal colon
samples. Interestingly, loss of sst2 and sst5 mRNA expression in
advanced stages was not demonstrated. A more recent study of
the same group (14), using in situ hybridization, demonstrated
that sst5 was by far the most expressed subtype in both normal
and tumor colonic tissues.
The controversial results of these studies might be ex-
plained by the methods used. Indeed, both RT-PCR and in situ
hybridization are not accurate enough in measuring sst2 gene
expression, and our previous experience in neuroblastoma
clearly showed that only a quantitative determination of sst2
gene expression was able to predict patient outcome. In fact, we
demonstrated that in neuroblastoma, where the receptor is
highly expressed, sst2 mRNA expression measurement not only
gave relevant insights in terms of patient overall and disease-
free survival but also represented the most relevant prognostic
factor for this kind of tumor (15).
Similarly, we tested whether sst2 expression may possibly
represent a prognostic factor for colon cancer. Furthermore, the
exact determination of its expression might help to identify
patients eligible for a new treatment modality based on SS
analogues conjugated with cytotoxic agents or with radio-emit-
ting molecules. Up to now, SS analogue therapy has been very
disappointing in the management of advanced malignancy. Im-
provements in the treatment of solid tumors are then likely to
come only from such therapies (16). A few studies showed that
cytotoxic SS analogues containing doxorubicin or 2-pyrrolino-
doxorubicin efficaciously inhibit growth of human breast and
prostate cancers expressing sst2 and sst5 and, therefore, can be
used for receptor-targeted chemotherapy in other sst-positive
tumors such as colon cancer (17, 18). In addition, in situ
radiotherapy with radiolabeled SS analogues has been success-
fully used for scintigraphic evaluation and management of pa-
tients with sst-positive neuroendocrine cancers (7, 19, 20).
The purpose of our study was to evaluate sst2 mRNA
expression in a large number of surgically removed colorectal
carcinomas by quantifying specific PCR products with an ac-
curate quantitative RT-PCR method with TaqMan reaction (21).
Moreover, sst2 mRNA expression was also quantified in paired
normal tissues to evaluate the different expression of sst2 in
tumor and normal colorectal tissues. However, quantitative RT-
PCR does not overcome one of the main limits of the PCR
procedures, which rely on the evaluation of a gene product
derived from a mixture of nucleic acid from different cell
populations. Therefore, in a limited number of patients, we
compared results obtained by real time RT-PCR with those
obtained by a semiquantitative in situ hybridization (15) per-
formed on the same samples and also with those obtained in
vivo, before surgery, by imaging with Octreoscan (22).
MATERIALS AND METHODS
Patients and Samples. Tissues were obtained from 103
patients with sporadic colorectal carcinoma (62 males and 41
females, age range: 46–89 years, mean  66.8) scheduled for
elective resection. In 17 unselected patients, SS receptor scin-
tigraphy with 111In-pentetreotide before surgery was also per-
formed. Informed consent was obtained previously from all of
the patients. For all of the patients at least one sample of both
neoplastic and normal tissue (taken 10 cm apart from the neo-
plasm) were obtained. Samples were immediately snap frozen
and stored in liquid nitrogen. Two patients were excluded from
the study, because their tumors were identified as a lymphoma
and as an epidermoid carcinoma. A third patient was excluded
because of the absence of malignant neoplasia. Tumor was
localized in the right colon in 34 patients, in the left colon (12
in the descending and 21 in the sigmoid colon) in 33 patients,
and in the rectal portion in the remaining 33 patients. Histolog-
ical examination was performed routinely in all of the cases. An
adequate number of sections was sampled from each tumor.
Slides were reviewed by the same pathologist without knowl-
edge of SS receptor status. Tumor histotype and grade of dif-
ferentiation were defined according to the WHO criteria (23).
The pattern of cancer growth was assessed as expanding (when
the tumor border was clearly demarcated) and as infiltrating
(when cancer cells spread into the surrounding tissues without a
distinct border; Ref. 24). All of the cases were staged according
to the original Dukes’ system. According to the histopatholog-
ical grading, 5 tumors were G1, 61 were G2, 8 were G3, and 16
were colloid; the other four showed a mixed pattern of G2 plus
colloid. Six were in situ tumors. CEA concentration, measured
before surgery, was available for 92 patients.
Total RNA was extracted from each sample with RNeasy
kit (Quiagen, Milan, Italy). Because sst2 is an intron-less gene,
each RNA sample was first submitted to a conventional PCR
with the same primers and cycling for sst2 but without reverse
transcription to exclude the presence of residual genomic DNA
in the extracted specimens. Samples with residual DNA were
treated with DNase until the disappearance of any DNA trace.
Quantitative Evaluation of sst2 mRNA Expression.
The primers and probe for sst2 mRNA quantification to use with
the ABI Prism 7700 Sequence Detection System were described
elsewhere (21). Total RNA (400 ng) is reverse-transcribed ac-
cording to recommended protocol. The PCR mixture contains
primers (200 mM each) and 200 nM of the Taqman probe in a
final volume of 25 l. Amplification and detection were per-
formed with the ABI Prism 7700 Sequence Detection System
with the following profile: one step at 50°C for 2 min, one step
at 95°C for 10 min, and 40 cycles at 95°C for 30 s and 60°C for
1 min. The amount of product was measured by interpolation
from a standard curve with RNA extracted from neuroblastoma
cell line CHP404, which overexpresses sst2 mRNA. CHP404
RNA (1 g) was reverse transcribed, and cDNA was then
serially diluted to obtain five standard solutions to be used in the
PCR reaction to generate the reference curve (21).
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sst2 Scintigraphy. Pentetreotide and 111In-chloride were
obtained from Mallinckrodt Medical BV. Radiolabeling was
performed according to the instructions of the manufacturer.
Patients were injected with 5 MBq/kg of 111In-pentetreotide i.v.
without any previous preparation. After the injection (3 h) a
planar whole-body acquisition was performed, with preset-
counts modality and with a 128  128 matrix, zoom 1.0, and
high-resolution collimator (only 172 keV peak). After the in-
jection (4 h) a tomographic acquisition was performed on the
suspected region of the body with a 64  64 matrix, zoom 1.0,
high-resolution collimator (only 172 keV peak), and 40 frames
for head of 454 s (three-head camera). After the administration
of 111In-pentetreotide (24 h), SPECT acquisition was then re-
peated with the same parameters on the same body region (22).
A tomographic reconstruction by filtered backprojection was
performed with convolution low-bass filter (cutoff 0.25 cycles/
pixel and filter order 4.0) for every tomographic registration
(22).
A normal ROI on the suspected area (ROIT) was drawn on
transaxial slice of the SPECT at 4 h; the same ROI was repo-
sitioned on the same area of the following SPECT at 24 h. The
ROI was also repositioned on the normal contralateral tissue
(ROINT) for every transaxial slice of the SPECTs. Then a ratio
between ROIT and the ROINT was calculated for every
transaxial SPECT slice. According to the SPECT time, ROIT:
ROINT ratios were evaluated at 4 h [(ROIT:ROINT)4 h] and 24 h
[(ROIT:ROINT)24 h]. If the activity in ROIT is attributable to
overexpression of sst2, the ROIT:ROINT ratio should increase
between the SPECT at 4 and 24 h. Conversely, if the activity in
ROIT at 4 h is attributable to “nonspecific” uptake, the ROIT:
ROINT ratio should be stable or decrease between 4 and 24 h
(22). The increase (ROIT:ROINT INC) of the ROIT:ROINT ratio
is expressed by:
ROIT:ROINT INC  [(ROIT:ROINT)24 h  (ROIT:
ROINT)4 h]/(ROIT:ROINT)4 h.
In Situ Hybridization. Frozen sections (7-m thick)
from both tumor and macroscopically uninvolved tissue samples
were collected onto gelatin/chrome alum-coated slides, dried
briefly on a hot plate at 80°C, and fixed in 4% paraformalde-
hyde/PBS, (pH 7.4) for 20 min. After three washes in PBS and
short air drying, sections were immediately used for in situ
hybridization. For the preparation of the RNA probe for sst2, the
284-bp fragment of the human sst2 cDNA obtained by RT-PCR
was subcloned into the appropriate restriction site of the plasmid
pGEM-T Vector (Promega, Madison, WI), as described previ-
ously (25, 26). Transcription and labeling of RNA probes were
performed using 60 Ci of [35S]-uridine-5-(-thio)-triphos-
phate (1250 Ci/mmol; New England Nuclear, Dreieich, Germa-
ny). The specific activity routinely obtained was 1.2–1.4  109
cpm/g. RNA probes were stored at 80°C and used within 2
weeks. Prehybridization, hybridization, removal of nonspecifi-
cally bound probe by RNase A digestion, and additional wash-
ing procedures were performed for positive- and negative-strand
RNA probes as described elsewhere (25).
Quantitative evaluation of sst2 mRNA expression was per-
formed by two independent observers who did not know the
results of real time RT-PCR with the aid of a computerized
video image analysis system (Quantimet Q500 MC; Leica Cam-
bridge Ltd., Cambridge, England). For the quantitation of in situ
hybridization results, six visual fields were chosen randomly
from each section and analyzed under a dark field microscope
equipped with a 20 lens. The autoradiographic signal corre-
sponding to the specific hybridization was acquired by a CCD
video camera connected to the microscope, converted to digital,
and transformed into pixel units. The threshold of specific
detection was automatically calibrated on control sections
hybridized with the corresponding sense probe. The results,
evaluated in terms of percentage of the total area occupied by
the sst2 autoradiographic signal, were expressed as mean 
SD (15).
Statistical Analysis. Statistical analyses were performed
with software from SPSS, Inc. (Chicago, IL). Significance of the
differences was evaluated by Student’s t tests for paired or
independent samples, or by one-way ANOVA, as indicated. In
matched tumor (T)-normal (N) pairs, the ratio between sst2
expression values (T:N) was considered increased (i.e., tumor
more than normal) when T:N  1.2 and decreased when T:N 	
0.8 (tumor less than normal).
RESULTS
Semiquantitative in Situ Hybridization. Twenty-six tu-
mors were analyzed by in situ hybridization. Specific sst2 gene
expression was observed in all of the malignant samples as well
as in the corresponding unaffected tissues examined (n  22).
Fig. 1 shows sst2 mRNA expression in representative sec-
tions of colon cancer and in the paired uninvolved mucosa. In
the normal colon, sst2 gene expression was predominantly lo-
calized in the epithelial cells lining the mucosal surface and
crypts. Weak autoradiographic labeling was also observed on a
few lamina propria mesenchymal cells. Smooth muscle cells of
the muscularis mucosae and propria, and the muscular wall of
larger submucosal blood vessels, were also positive. Of note, a
prominent autoradiographic signal was sometimes found on
inflammatory cells of the normal mucosa adjacent to well-
differentiated neoplasms (Fig. 1, a and b).
In tumor samples, a relatively homogeneous autoradio-
graphic signal was found throughout all of the malignant cells
(Fig. 1, c–f). Specific labeling was also noted on some cells
sparsely distributed in the peritumoral stroma which, on the
basis of their morphology, were tentatively identified as inflam-
matory cells (e.g., lymphocytes and macrophages) and fibro-
blasts. In addition, endothelial cells of capillaries and venules
displayed low but still detectable sst2 mRNA expression. Lend-
ing support to the specificity of these results, control sections
hybridized with the sense (anticomplementary, negative control)
sst2 probe displayed only a limited number of autoradiographic
grains, which cannot be distinguished from the background
labeling (Fig. 1, g and h).
The semiquantitative evaluation of the positive autoradio-
graphic signals indicated that sst2 expression was quite variable
in the 26 tumors examined (2.9–16.4% total area with a mean
value of 9.12  3.91).
Semiquantitative in Vivo sst2 Scintigraphy. We found
ligand binding in all of the 17 patients investigated with the
semiquantitative 111In-pentetreotide sst2 scintigraphy. In 13 of
them we found a specific temporal increase in ROIT:ROINT
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ratio (mean increase: 78.92  23.11%; range 3–295%). Among
these patients the increase was 	45% in 6 of 13 subjects and
45% in 7 of 13 subjects. In the other 4 patients the increase in
ROIT:ROINT ratio was absent. Fig. 2 shows representative
SPECT in two patients who were classified, on the basis of this
method, as positive and negative for the presence of SS-binding
sites, respectively.
Quantitative RT-PCR. All of the tumor tissues ana-
lyzed with real time RT-PCR showed sst2 gene expression.
Nevertheless, the level of this expression was quite variable,
ranging from 7.9  105 to 1.2  109 molecules/g of total
RNA, with a mean value of 10.3  1.9  107. Results obtained
in colorectal carcinoma with real time RT-PCR were signifi-
cantly related with those derived from the two aforementioned
techniques. Thus, we found significantly positive relationships
among measurements of sst2 expression obtained by real time
RT-PCR and in situ hybridization (r  0.51; P 	 0.01; n  26)
or by real time RT-PCR and in vivo imaging with 111In-pente-
treotide (r  0.51; P 	 0.05; n  17).
Relationship between sst2 Expression in Colorectal
Carcinoma and Clinical-Pathological Features. Table 1
shows the mean values ( SE) of sst2 mRNA expression in
colorectal carcinoma as evaluated by either in situ hybridization
(n  26) or RT-PCR (n  100), as a function of the most
common clinical-pathological features for colorectal carcinoma.
One-way ANOVA did not find statistically significant associa-
tions between sst2 expression and any of the clinical-patholog-
ical parameters investigated. It is interesting to note that patients
Fig. 1 Dark- and bright-field photomicro-
graphs showing in situ hybridization to sst2
mRNA with antisense (a–f) and sense (g and
h) 35S-labeled RNA probes. Intense sst2
mRNA expression is evident in the normal
mucosa adjacent to a well-differentiated can-
cer of the left colon (a); a bright-field pho-
tomicrograph at greater magnification clearly
shows sst2 mRNA expression in inflammatory
cell of the lamina propria (b); strong sst2 ex-
pression is also noted in malignant cells from
the corresponding tumor (c and d), whereas
very low amounts of sst2 RNA transcripts are
evident in a representative section from a can-
cer of the right colon (e and f); a control
section hybridized with the sense anticomple-
mentary probe shows only nonspecific back-
ground signal (g and h). Exposure time: 6
weeks. Original magnification: a, c, e, and g,
130; b, d, f, and h, 260.
422 Somatostatin Type 2 Expression in Colorectal Cancer
with an elevated value of preoperative CEA (5 ng/ml) express
a lower concentration of sst2 mRNA than patients with normal
CEA levels, even if this difference is not statistically significant
(P  0.06 for in situ hybridization and P  0.13 for RT-PCR).
Relationship between sst2 Expression in Colorectal
Carcinoma and the Corresponding Unaffected Colorectal
Samples. sst2 gene expression was also evaluated in the ad-
jacent unaffected colorectal mucosa by both real time RT-PCR
(n  100) and semiquantitative in situ hybridization (n  22).
Even in these normal colorectal samples, the expression of sst2
showed a large variability when analyzed either by real time
RT-PCR (2.9  105-2.8  109 molecules/g total RNA, with a
mean value of 16  3.8  107) or by semiquantitative in situ
hybridization (4.46–16.49% total area, with a mean value of
9.0  0.6). Table 1 also shows the results obtained by real time
RT-PCR in the unaffected colorectal tissue as well as in the
corresponding cancer samples for comparison. The matched
tumor-normal pairs showed a higher sst2 gene expression in the
tumor than in the corresponding normal tissues in 35 subjects
(35%; T:N 1.2), whereas in 56 patients we found the opposite
(56%; T:N 	 0.8). In 9 patients, the levels of sst2 expression in
the normal and pathological tissues were rather similar (0.8 
T:N  1.2). We did not find any statistically significant differ-
ence in sst2 expression between normal and tumor samples,
although malignant tissue tends to express a lower abundance of
sst2 than the normal mucosa. A lack of significant difference
was also found when normal and pathological tissues were
compared according to sex, age, localization, stage, and grading
of disease. However, as reported in Table 1, patients with
elevated concentrations of CEA (5 ng/ml) had a significantly
lower sst2 mRNA expression in tumors (5.7  1.74  107
molecules/g of total RNA) when compared with the corre-
sponding normal tissue (19.6  6.29  107 molecules/g of
total RNA; P  0.028). Such a difference was not found in
patients with normal concentrations of CEA (	5 ng/ml; 11.9 
2.83  107 versus 15.8  5.27  107 molecules/g of total
RNA; P  0.509).
We did not find any significant difference when matched
tumor-normal pairs of colorectal carcinoma were evaluated by
semiquantitative in situ hybridization (not shown). The ratio
Fig. 2 Typical SPECT studies in two
patients with colorectal cancer. After
111In-pentetreotide injection, ROIs were
extracted at two different times in three
consecutive slices (A, after 4 h, first three
boxes; B, after 24 h, last three boxes) in
pathological (ROIT, circles a) and normal
(ROINT, circles b) tissues. The ratio
ROIT:ROINT was then calculated. The
first number at the top of each box repre-
sent counts/pixels in pathological tissue,
while the second one represents counts/
pixels in the selected normal tissue. Be-
low these numbers, the individual ratio
between values is also reported. Calcu-
lated mean ratio ROIT:ROINT is shown in
an additional box at 4 h (Mean A) and
24 h (Mean B) in each panel. Top panel,
patient with a specific increase between 4
and 24 h in ROIT:ROINT. Bottom panel,
patient without increase between 4 and
24 h in ROIT:ROINT. The increase (ROIT:
ROINT INC) of the ROIT:ROINT ratio is
expressed by ROIT:ROINT INC 
[(ROIT:ROINT)24 h  (ROIT:ROINT)4
h]/(ROIT:ROINT)4 h.
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between tumor and normal (T:N) values was increased in
45.5%, decreased in 40.9%, and similar in 13.6%.
DISCUSSION
In this study we reported the largest series of colorectal
carcinoma thus far investigated for the evaluation of the expres-
sion of sst2, which binds with the highest affinity clinically
available SS analogues.
In recent years, several laboratories provided evidence for
the expression of SS receptors in colorectal carcinoma. Such
evidence was mainly based on radioligand-binding procedures
performed on membranes (8, 27) or tissue slices (28) from
limited series of primary colorectal carcinomas or from colo-
rectal carcinoma cell lines. Studies in vitro on colorectal carci-
noma cell lines (29–32) or in vivo in nude mice bearing colo-
rectal carcinoma cell xenografts (29, 33) indicated that treatment
with SS or its analogues greatly decreased growth of several but
not all of the colorectal carcinoma cell lines. Indeed, no effect of
SS was observed in SS receptor-negative cell lines (34), indi-
cating that the antiproliferative effect of SS in colorectal carci-
noma cells was mediated by the expression of specific receptors
(35). In the meantime, SS analogues labeled with 123I or 111In
for the in vivo imaging of SS-binding sites have been developed
and used in nuclear medicine to visualize receptor-positive
tumors, including colorectal carcinoma and their metastases
(36). Results from these studies prompted several clinical trials
to test the relative efficacy of SS analogue treatment in patients
with colorectal carcinoma (37–42). In a subset of patients, a
short-term octreotide therapy decreased markers of cell prolif-
eration in the primary tumor (38, 40). However, in the majority
of trials, SS analogue therapy has been very disappointing in
terms of survival or disease stabilization (37, 41, 42). Only in a
relatively recent study a significant advantage in terms of sur-
vival was reported (39). These contradictory findings might be
explained by the different dose of SS analogues given to patients
in the different trials or, most probably, by the inappropriate
selection of patients (advanced colorectal carcinoma). Indeed,
advanced colorectal carcinoma might express less sst2 receptors
than early stage tumors. In fact, some (11) but not all (12, 13) of
the previous studies indicated a loss of sst2 in the most advanced
stages of the disease. Because sst2 receptor expression has not
been studied in any of these clinical trials, it is possible that
colorectal cancer patients with a low concentration of sst2 were
also treated with SS analogues (11). In addition, it is possible
that the antineoplastic activity of SS analogues does not produce
an adequate clinical response as adjuvant therapy to surgery or
Table 1 sst2 mRNA expression in colorectal tumor and corresponding normal tissues, measured by in situ hybridization by
quantitative RT-PCR
In situ hybridization in neoplastic tissue
Real time RT-PCR
Neoplastic tissue Normal tissue
Normal vs
neoplastic
n Mean SE
One-way
Anova n Mean SE
One-way
Anova Mean SE
One-way
Anova
Student’s t
test
Total 26 9.12a 3.91 100 1.0  108b 1.9  107 1.6  108b 3.8  107 P  0.17c
Age
	55 2 10.35 3.75 P  0.79 8 9.2  107 5.4  107 P  0.84 2.5  108 1.6  108 P  0.56 P  0.20
55 24 9.09 0.80 92 1.0  108 2.1  107 1.5  108 3.9  107 P  0.28
Sex
Males 16 8.89 1.07 P  0.61 60 1.1  108 2.6  107 P  0.56 2.1  108 6.1  107 P  0.13 P  0.15
Females 10 9.67 1.08 40 9.0  107 3.0  107 9.0  107 1.8  107 P  0.98
Localization
Right 10 8.73 1.36 P  0.88 34 5.7  107 1.3  107 P  0.10 1.7  108 8.3  107 P  0.18
Left 10 9.66 1.27 32 1.6  108 4.8  107 1.7  108 6.3  107 P  0.96 P  0.95
Rectum 6 9.18 1.46 34 9.86  107 3.2  107 1.5  108 4.4  107 P  0.29
Dukes’ stage
A 6 9.50 1.59 P  0.99 14 7.0  107 3.3  107 P  0.54 1.6  108 9.3  107 P  0.81 P  0.19
B 7 8.77 1.47 46 1.3  108 3.5  107 1.7  108 4.7  107 P  0.53
C 7 9.30 1.39 31 8.2  107 3.0  107 1.8  108 9.0  107 P  0.33
D 6 9.25 2.10 9 7.0  107 4.2  107 4.3  107 1.8  107 P  0.60
Grading
G0/G1 5 9.92 0.88 P  0.17 11 2.2  107 9.5  106 P  0.28 5.9  107 2.4  106 P  0.15
G2/G3/mix 17 9.59 1.02 74 1.2  108 2.5  107 1.9  108 5.0  107 P  0.30 P  0.18
Colloids 4 6.57 2.11 15 7.2  107 3.8  107 6.2  107 1.9  107 P  0.69
Pattern
Infiltrating 11 8.64 1.34 P  0.57 57 1.08  108 2.33  107 P  0.93 1.6  108 5.8  107 P  0.67 P  0.42
Pushing 12 9.63 1.12 36 1.12  108 4.06  107 1.9  108 5.0  107 P  0.18
CEA
	5 ng/ml 16 10.17 0.84 P  0.06 60 1.2  108 2.8  107 P  0.13 1.6  108 5.3  107 P  0.64 P  0.51
5 ng/ml 9 6.92 1.34 32 5.7  107 1.7  107 2.0  108 6.3  107 P  0.03
a Percentage of total area.
b Molecules of sst2 mRNA/g total RNA.
c t test for paired samples.
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chemotherapy, even in patients expressing a relative abundance
of sst2. However, it is important to understand whether tumor
sst2 expression is higher or at least not lower than the expression
of unaffected mucosa. Hence, the present study is important for
the following reasons: (a) it provides a quantitative estimation
of sst2 expression in a rather large cohort of colorectal carcino-
mas; (b) it reports the simultaneous determination of sst2 in
tumor as well as in the neighboring normal mucosa; and (c) it
uses three different methods to evaluate sst2 expression.
We essentially found that all of the 100 colorectal carci-
noma tumors expressed measurable amounts of sst2 mRNA
when analyzed by real time RT-PCR, with a mean value of
expression (1.03  108 molecules/g of total RNA) not so
different from the mean value (9.8  108 molecules/g of total
RNA) reported by our group in neuroblastoma, a pediatric
neuroendocrine tumor (15). Accordingly, a positive signal for
sst2 gene was detected by in situ hybridization in all of the
tumors, although the size of the sample analyzed was limited
(n  26). It is important to note that quantitative results on sst2
mRNA as derived by RT-PCR and by in situ hybridization
evaluation are significantly related. This result is in perfect
agreement with a previous report on neuroblastoma (15). An
important finding of the in situ hybridization study was that the
autoradiographic labeling was not only present in tumor cells
but also on blood vessels, inflammatory cells, and even in the
epithelial and mesenchymal cells of the surrounding unaffected
mucosa. Accordingly, we did not find any significant difference
in sst2 expression when matched tumor-normal pairs were an-
alyzed by either quantitative RT-PCR or in situ hybridization,
although, on average, tumor samples expressed a lower amount
of sst2 mRNA than the unaffected samples. In fact, about half of
the tumor samples showed a lower expression of sst2 mRNA
than the corresponding unaffected tissues (RT-PCR or in situ
hybridization). In line with this observation are the results of the
preoperative in vivo imaging of colorectal carcinoma patients
with 111In-pentetreotide performed in a small subgroup of these
patients. Semiquantitative evaluation of 111In-pentetreotide up-
take indicates a high increase in the ROIT:ROINT ratio (45%)
and, therefore, a high density of octreotide binding sites (34) in
only a fraction of patients (7 of 17). Interestingly, we found a
significant positive correlation between quantitative results of
111In-pentetreotide scintigraphy and RT-PCR, as reported pre-
viously in an other study (22). These findings indicate that only
a minority of colorectal carcinomas shows an increased expres-
sion of sst2 gene and protein in tumors when compared with the
corresponding normal tissue. Therefore, only a minority of
colorectal carcinoma might be successfully targeted with SS
analogues for diagnostic or therapeutic purposes. Our results are
in agreement with several previous observations showing, in
more limited series, a low abundance of sst2 in colorectal
carcinoma (8, 27, 28).
Analysis of the distribution of sst2 gene expression in
colorectal carcinoma as a function of several clinical-patholog-
ical features did not show any statistically significant relation-
ship between tumor sst2 expression and any of the parameters
examined, including localization, grading, or stage of the dis-
ease. The same results were obtained when matched tumor-
normal colorectal carcinoma pairs were analyzed. Hence, we
cannot confirm that there is a loss of sst2 expression in more
advanced stages of the disease (11). However, we found that
patients with an elevated preoperative CEA (5 ng/ml) showed
a significantly lower expression of sst2 (three-fold) in the tumor
than in the corresponding unaffected tissue. The CEA gene is
one of the most widely expressed genes in colorectal carcinoma
cells. CEA protein sheds in elevated amounts in peripheral
circulation in about half of the patients with colorectal carci-
noma (43). Preoperative measurement of CEA protein concen-
tration is, up to now, the only serum marker recommended for
staging and surgical treatment planning in colorectal carcinoma
(44, 45). Postoperative serum CEA protein measurement is also
the most effective approach to follow the course of colorectal
carcinoma (46, 47). In addition, an elevated preoperative CEA
level is generally accepted as a poor prognostic indicator (45,
48). The finding that sst2 gene expression is markedly reduced
in tumor samples of patients with elevated CEA concentrations
suggests that sst2 gene expression in colorectal carcinoma might
be related to a favorable outcome, as we reported previously for
the neuroendocrine tumor neuroblastoma. However, the prog-
nostic relevance of sst2 determination in colorectal carcinoma
should still be demonstrated in long-term follow-up of patients.
In conclusion, our study, based on a quantitative PCR
approach, seems to give a direct confirmation to previous qual-
itative findings (11), demonstrating that colorectal carcinoma
does not express a high abundance of sst2 but tends to express
a lower receptor concentration when compared to the corre-
sponding unaffected tissue. Loss of sst2 seems to be a relevant
event in patients with elevated preoperative concentration of
CEA, a poor prognostic indicator for colorectal carcinoma.
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